0% drop-out rates
We integrate successful patient-centered communication into all of our projects. It translates into 0% drop-out rates, like in our recent Phase 1 study, for which 225 healthy volunteers had been recruited over 4 months and all of them have been continuing the study despite/although very long follow-up period.
On-site infrastructure
Our on-site infrastructure is a part of the boutique full-package service for your early drug development. Explore our website for more information about our specialised Intensive Care Unit and let us guide you through your first-in-human clinical trials.
Patients talk, we listen
Patient satisfaction scores are increasingly relevant in drug development – when they talk, we listen. Our latest survey evaluating clinical trial participant satisfaction indicated that 79% of surveyed patients had awarded us 5-star ratings for patient experience.
Unique infrastructure for early drug development
We offer a unique infrastructure to support your early drug development. Our on-site Emergency Room and Intensive Care Unit are two features of the boutique full-package service, guiding you through your first-in-human clinical trials.
Oncology trials reached historically high levels in 2021
According to the new released IQVIA Report, Oncology trial starts reached historically high levels in 2021, up 56% from 2016 and mostly focused on rare cancer indications. Growing understanding of the biology of malignancies allows us to shift towards targeted therapies or enable personalized treatments. Read more at: Global Oncology Trends 2022
Visit our booth on annual conference of AFPT in Paris
The 19th annual conference of Association Française de Pharmacologie Translationnelle (AFPT) – Le Club Phase 1 in Paris kicked off yesterday! We are excited to learn and share knowledge about innovative tools and approaches in translational and clinical pharmacology. Our team is on the ground ready to connect and discuss how best we can assist you with your […]
The costs of developing biosimilar drugs can be reduced
The higher the biosimilarity and risk-benefit demonstrated via quality assays and comprehensive comparability studies with a reference medicine, the shorter the clinical trial programs for a biosimilar are likely to be accepted by the regulators.
Virtual realm
We’re facing a new reality in clinical trials – communication methods and trial conduct adapt to the virtual realm. We are increasingly flexible to the needs of our partners based in different regions – ensuring that they deliver life-saving medicines and make evidence-driven decisions with confidence, regardless of the distance.
Stop letting patient recruitment problems!
It is time to stop letting patient recruitment problems impact your early-phase study timelines. Our site staffs work continuously to boost our extensive database covering a range of ages and health conditions, preparing it even for the most requiring business partners.
International Clinical Trials Day
Friday’s International Clinical Trials Day organised by INFARMA – The Employers’ Union of Innovative Pharmaceutical Companies, POLCRO and GCPpl was such a great opportunity to listen to industry voices on the future of clinical trials. The challenges brought by the pandemic have visibly accelerated the digitization of healthcare and clinical research. As a result, we have recently observed the […]
